BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 17695527)

  • 1. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y; Harada K; Ferdous T; Yoshida H
    Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
    Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
    Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
    Ishida H; Yamada H; Shirakawa K; Nakada H; Ohsawa T; Takeuchi I; Okada N; Yokoyama M; Inokuma S; Suzuki T; Odaka A; Hoshino T; Murata N; Hashimoto D; Itoyama S; Mori T; Matsumoto Y; Miura T
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1621-6. PubMed ID: 14619479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells.
    Harada K; Kawaguchi S; Supriatno ; Onoue T; Yoshida H; Sato M
    Oral Oncol; 2004 Aug; 40(7):713-9. PubMed ID: 15172641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice.
    Ishikawa Y; Kubota T; Otani Y; Watanabe M; Teramoto T; Kumai K; Kitajima M; Takechi T; Okabe H; Fukushima M
    Clin Cancer Res; 1999 Apr; 5(4):883-9. PubMed ID: 10213225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of members of the tumor necrosis factor alpha-related apoptosis-inducing ligand pathway in prostate cancer cells.
    Sridhar S; Ali AA; Liang Y; El Etreby MF; Lewis RW; Kumar MV
    Cancer Res; 2001 Oct; 61(19):7179-83. PubMed ID: 11585752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
    Fan QL; Zou WY; Song LH; Wei W
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):189-96. PubMed ID: 15290100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
    Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X
    Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
    Ichikawa W; Uetake H; Shirota Y; Yamada H; Nishi N; Nihei Z; Sugihara K; Hirayama R
    Clin Cancer Res; 2003 Feb; 9(2):786-91. PubMed ID: 12576451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
    Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
    Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice.
    Xiang H; Nguyen CB; Kelley SK; Dybdal N; Escandón E
    Drug Metab Dispos; 2004 Nov; 32(11):1230-8. PubMed ID: 15282212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer: relationship between mRNA expression and activity.
    Miyoshi T; Kondo K; Fujino H; Takahashi Y; Sawada N; Sakiyama S; Tsuyuguchi M; Kimura S; Sumitomo M; Monden Y
    Anticancer Res; 2005; 25(2A):923-30. PubMed ID: 15868929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study.
    Kawasaki G; Yoshitomi I; Yanamoto S; Mizuno A
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Dec; 94(6):717-23. PubMed ID: 12464897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
    J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft.
    Huang X; Lin T; Gu J; Zhang L; Roth JA; Stephens LC; Yu Y; Liu J; Fang B
    Gene Ther; 2002 Oct; 9(20):1379-86. PubMed ID: 12365003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.
    Mizutani Y; Yoshida O; Miki T; Bonavida B
    Clin Cancer Res; 1999 Sep; 5(9):2605-12. PubMed ID: 10499639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation between 5-fluorouracil (5-FU) sensitivity as measured by collagen gel droplet embedded culture drug sensitivity test (CD-DST) and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer].
    Ochiai T; Sugitani M; Nishimura K; Noguchi H; Watanabe T; Sengoku H; Kihara A; Okano M
    Gan To Kagaku Ryoho; 2001 May; 28(5):661-7. PubMed ID: 11383215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation between clinical pathophysiologic factors and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer].
    Ochiai T; Sugitani M; Nishimura K; Noguchi H; Watanabe T; Sengoku H; Komiyama H; Okano M
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):413-20. PubMed ID: 11915731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.